Uso de corticoide para aceleração da maturidade pulmonar fetal na pre-eclampsia grave
AUTOR(ES)
Melania Maria Ramos de Amorim
DATA DE PUBLICAÇÃO
1998
RESUMO
BACKGROUNO - Efficacy of antenatal corticosteroid therapy for reduction of incidence of hyaline membrane disease (HMO) in severe preeclampsia as well possible maternal and fetal si de effects have never been established in wellcontrolled studies. OBJECTIVES - To determine efficacy for prevention of HMO and maternalperinatal outcomes of corticosteroid therapy in pregnant women with severe preeclampsia. SUBJECTS ANO METHOOS - A prospective, double-blind, randomized trial was performed, enrolling 218 pregnant women with severe preeclampsia and gestational age between 26-34 weeks; 110 received betamethasone (12 mg 1M, weekly) and 108 received placebo. Inclusion criteria were singleton pregnancies with well-documented gestational age, alive fetus at admission and interval treatment-delivery >24h. Exclusion criteria were premature rupture of membranes, maternal diseases and congenital malformations. Statistical analysis included means difference and chi-square test. Relative risk (and 95% confidence interval) of HMO was calculated for corticosteroid use, stratifying for gestational age. It was also calculated the relative risk for corticosteroid therapy of other neonatal events (necrotizing enterocolitis, intraventricular hemorrhage, patent ductus arteriosus, bronchopulmonary dysplasia, neonatal infection and perinatal mortality) and maternal complications (pulmonary edema, aggravating hypertension, HELLP syndrome, maternal infection, acute renal failure and death). RESUL TS - Frequency of HMO was significantly reduced in corticosteroid group (23%) when compared to placebo group (43%), with a relative risk of 0,53 (0,35-0,82) and an adjusted risk by gestational age of 0,56. Relative risk of intraventricular hemorrhage, patent arteriosus ductus and perinatal infection
ASSUNTO(S)
mortalidade perinatal gravidez - complicações e sequelas hipertensão na gravidez
